Stellula Therapeutics is a biotechnology company developing next-generation gene therapies for rare and devastating neurological disorders. Our lead program, STEL8, uses advanced gene editing technology to target SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE)—a severe pediatric genetic disorder caused by mutations in the Nav1.6 sodium channel.
Current treatment options for SCN8A-DEE are limited, symptom-based, and often ineffective. At Stellula, we take a curative approach—correcting the underlying genetic mutations to deliver a permanent fix for life. In preclinical models, STEL8 has demonstrated promising results: improved survival, reduced seizures, and restoration of normal neuronal activity.
Co-founded by experts in sodium channel biology and gene editing, Stellula is at the forefront of precision neurotherapeutics. We are driven by a singular mission: to give children with genetic epilepsies a real chance at life.
Company Details
- Employees
- 1
- Address
- Charlottesville, Virginia 22903, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Chesterfield.
- HQ
- Charlottesville, Virginia
Stellula Therapeutics Questions
Stellula Therapeutics's LinkedIn profile is https://www.linkedin.com/company/stellula-therapeutics
Stellula Therapeutics has
1 employees.
View email and phone details for 1
employees at Stellula Therapeutics.
Stellula Therapeutics's industry is
Biotechnology Research
Stellula Therapeutics's top competitors are
Open Bio Labs,
Gemini Ai,
Gro52,
Kinnakeet Biotechnology Llc,
Horticrystal,
Metabaxis,
Ace Biotex Co.,
Durahuman Technologies,
American International Biotechnology Aibiotech,
Vidrio Technologies.
Stellula Therapeutics's categories are Biotechnology Research
